HOME › DRUGS › RESMETIROM
ACTIVE SUBSTANCE / INN

RESMETIROM

Brand name(s): Rezdiffra, REZDIFFRA
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Non-alcoholic Fatty Liver Disease;Liver Cirrhosis
NDA217785
ACTIVE SUBSTANCE
Resmetirom
REGULATORS
FDA · EMA
SPONSORS / MAH
Madrigal Pharmaceuticals EU Limited, MADRIGAL
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
REZDIFFRANDA217785MADRIGALPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
RezdiffraMadrigal Pharmaceuticals EU LimitedAuthorised18/08/2025Non-alcoholic Fatty Liver Disease;Liver Cirrhosis

FULL INTELLIGENCE ON RESMETIROM

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →